Logo
JNJ logo
Johnson & Johnson
JNJ
176.53 (-1.07%) 1.89
425.14(B)
Health Care
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of various products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as immunology including rheumatoid arthritis psoriatic arthritis inflammatory bowel disease and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience consisting of mood disorders neurodegenerative disorders and schizophrenia; oncology such as prostate cancer hematologic malignancies lung cancer and bladder cancer; cardiovascular and metabolism including thrombosis diabetes and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips knees trauma spine sports and other; surgery portfolios comprising advanced and general surgery technologies as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers hospitals and retailers as well as physicians nurses hospitals eye care professionals and clinics. The company was founded in 1886 and is based in New Brunswick New Jersey.
My Holdings:
(?% ownership)
Shares:
Cost basis:
Market cap:$425.14(B)
EV:$457.03(B)
Total Equity:$78.47(B)
Div. yield:2.84%
Earnings date:Oct-14-2025
P/E:18.74
P/E (fwd):16.27
P/FCF:22.90
P/S:4.69
P/B:5.42
EPS:$9.4
EPS (fwd):$10.8
FCF/share:$7.7
Dividend/share:$5.0
Book value/share:$32.6
ROIC:18.7%
ROA:12.1%
ROE:30.2%
Gross margin:68.4%
Net margin:25.0%
Valuation Summary TTM Financials Growth Estimates Historical Data KPIs Similar Companies Ownership Tools

JNJ Valuation & Price Targets

Current Price
$177
Day change: -1.07%
PEvaluation
N/A
N/A
Analyst targets
N/A
N/A

More Valuation Methods

DCF (2-stage)
N/A
N/A
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
Future P/E
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
DDM
N/A
N/A

PEvaluation

11% overvalued
Low
$118
Mid
$158
High
$197
Current price
$177
Fair P/E
Margin of safety
Market Model
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+110.610.811.023
FY+210.811.312.125
FY+310.912.113.018
FY+411.312.613.66
FY+512.313.514.96
EPS

Analyst Price Targets

1% overvalued
Low
$155
Mid
$175
High
$200
Current price
$177

Analyst Recommendations

Strong Buy2
Buy8
Hold14
Sell0
Strong Sell0

EPS Estimates

LowAvgHigh#
FY+110.610.811.023
FY+210.811.312.125
FY+310.912.113.018
FY+411.312.613.66
FY+512.313.514.96

2-stage DCF

First Stage Duration
Starting Free Cash Flow
First Stage Growth Rate
Terminal Growth Rate
Discount Rate

Discounted Cash Flow

Forecast years
Terminal Growth Rate
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years
Exit FCF Multiple
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Future P/E Valuation

Projection Years
Base Revenue
Revenue Growth Rate
Final Net Margin
Final P/E Ratio
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

Dividend Discount Model

Annual Dividend
First Stage Length (Years)
First Stage Growth Rate
Final Growth Rate
Discount Rate

Summary

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$90.63(B)
Gross profit$62.00(B)
EBITDA$30.25(B)
Net income$22.66(B)
Gross margin68.4%
Operating margin24.5%
Net margin25.0%
Shares outstanding:2.41(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$193.39(B)
Current assets$54.50(B)
Total liabilities$114.92(B)
Current liabilities$54.18(B)
Cash & Short-term inv.$18.88(B)
Long-term debt$39.23(B)
Total intangibles$97.95(B)
PP&E$21.95(B)

Cash flow (TTM)

CFOCFICFF
FCF$18.55(B)
CapEx$-4.48(B)
Dividends paid$-12.09(B)
Stock issued$1.10(B)
Stock repurchased$-2.95(B)
Stock-based comp.$1.23(B)
Debt issued$19.79(B)
Debt repaid$-12.01(B)

Per share data (TTM)

Price: $177
Revenue: $37.6 (4.7x | 21.3%) Gross profit: $25.7 (6.9x | 14.6%) Earnings: $9.42 (18.7x | 5.3%)
FCF: $7.71 (22.9x | 4.4%) Stock-based Comp.: $0.51 (345.4x | 0.3%) Dividend: $5.02 (35.2x | 2.8%)
Total Assets: $80.3 (2.2x | 45.5%) Total Liabilities: $47.7 (3.7x | 27.0%) Book Value: $32.6 (5.4x | 18.5%) Cash & ST inv.: $7.84 (22.5x | 4.4%) Debt: $16.3 (10.8x | 9.2%)

Growth Estimates

Revenue

CAGR: 4.6%
FY+1FY+2FY+3FY+4FY+5
FY+1$93.40(B)
FY+2(+4.2%)$97.35(B)
FY+3(+4.3%)$101.57(B)
FY+4(+4.9%)$106.55(B)
FY+5(+4.8%)$111.66(B)

Net Income

CAGR: 4.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$26.23(B)
FY+2(+4.3%)$27.35(B)
FY+3(+6.5%)$29.12(B)
FY+4(+2.0%)$29.71(B)
FY+5(+7.0%)$31.78(B)

EPS

CAGR: 5.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$10.85
FY+2(+4.6%)$11.35
FY+3(+6.7%)$12.11
FY+4(+3.7%)$12.56
FY+5(+7.7%)$13.53

FCF per share

CAGR: 2.2%
FY+1FY+2FY+3
FY+1$13.70
FY+2(-8.0%)$12.61
FY+3(+13.5%)$14.31

Historical Financials

Showing limited histrical data.
YearlyQuarterly
Income
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.020.0(B)40.0(B)60.0(B)80.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.05.0(B)10.0(B)15.0(B)20.0(B)
Stock-based Comp. FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.050.0(B)100.0(B)150.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.02.04.06.08.010.012.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.05.010.015.020.025.0
P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240%10%20%30%40%50%60%70%
Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin
Returns
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240%5%10%15%20%25%30%
ROIC ROAROCEROE
Shares outstanding
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.0500.0(M)1.0(B)1.5(B)2.0(B)2.5(B)
Shares (Basic)Shares (Diluted)
Market Cap.
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY20240.0100.0(B)200.0(B)300.0(B)400.0(B)
Market Cap.

KPIs

Revenue By Geography
10/20223/20236/20239/202312/20233/20246/20249/202412/20243/2025
Western Hemisphere Excluding US Asia Pacific and Africa US Europe
Revenue By Segment
12/20223/20236/20239/202312/20233/20246/20249/202412/20243/2025
Medtech Pharmaceutical Consumer Health

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.06%
Institutions: 74.38%
Other: 25.56%

Institutional ownership

9.84% Vanguard Group Inc8.46% Blackrock Inc.5.56% State Street Corporati...2.52% Geode Capital Manageme...2.33% JPMORGAN CHASE & CO1.91% Morgan Stanley1.32% State Farm Mutual Auto...1.28% Northern Trust Corpora...1.26% NORGES BANK1.14% Bank of America Corpor...38.76% Others

Trading Summary

In the past year, insiders have bought $147220 worth of the company's stock, and sold $7.29(M).

Congress members have bought between $88032 - $620000 worth of the company's stock, and sold between $325022 - $1.02(M).

Insider transactions

2025-09

$0.00
$0.00

2025-08

$0.00
$0.00

2025-07

$3.13(M)
$0.00

2025-06

$0.00
$0.00

2025-05

$0.00
$0.00

2025-04

$0.00
$0.00

2025-03

$0.00
$0.00

2025-02

$3.23(M)
$0.00

2025-01

$0.00
$0.00

2024-12

$0.00
$147220

2024-11

$0.00
$0.00

2024-10

$0.00
$0.00

2024-09

$0.00
$0.00
DateSharesTotal ($)Price ($)NameTitle
Sell2025-07-1719,1373,129,830163.5REED JOHN COfficer
Grant2025-03-18130,85200.0DUATO JOAQUIN BOIXChief Executive Officer
Grant2025-02-256,999712,988101.9DECKER ROBERT JOfficer
Sell2025-02-256,9991,160,994165.9DECKER ROBERT JOfficer
Sell2025-02-1840362,928156.1SCHMID TIMOTHYOfficer
Grant2025-02-0713,0151,302,281100.1WOLK JOSEPH JChief Financial Officer
Grant2025-02-0732,7623,278,166100.1WENGEL KATHRYN EChief Operating Officer
Grant2025-02-0758,5045,853,910100.1TAUBERT JENNIFER LOfficer
Grant2025-02-07126,36912,644,482100.1DUATO JOAQUIN BOIXChief Executive Officer
Sell2025-02-0713,0152,002,878153.9WOLK JOSEPH JChief Financial Officer
Buy2024-12-121,000147,220147.2WEINBERGER MARK ADirector
Grant2024-10-1768,89000.0WOLK JOSEPH JChief Financial Officer
Grant2024-08-305,635563,838100.1DECKER ROBERT JOfficer
Sell2024-08-305,635930,113165.1DECKER ROBERT JOfficer

Congressional trading

2025-09

$0.00
$0.00

2025-08

$0.00
$0.00

2025-07

$0.00
$0.00

2025-06

$113503
$8001

2025-05

$91002
$64503

2025-04

$40003
$24002

2025-03

$183001
$81002

2025-02

$0.00
$0.00

2025-01

$24002
$56004

2024-12

$175001
$32002

2024-11

$0.00
$40003

2024-10

$40501
$0.00

2024-09

$8001
$8001
DatePoliticianPartyChamberAmount ($)
Sell2025-06-23Ro KhannaDHouse$15,001 - $50,000
Sell2025-06-20Ro KhannaDHouse$1,001 - $15,000
Sell2025-06-20Ro KhannaDHouse$1,001 - $15,000
Sell2025-06-16Scott FranklinRHouse$15,001 - $50,000
Sell2025-06-12Pete SessionsRHouse$15,001 - $50,000
Buy2025-06-10Lloyd DoggettDHouse$1,001 - $15,000
Buy2025-05-30Gilbert Ray Cisneros, Jr.DHouse$15,001 - $50,000
Sell2025-05-28Ro KhannaDHouse$1,001 - $15,000
Sell2025-05-19Ro KhannaDHouse$1,001 - $15,000
Sell2025-05-12Jefferson ShreveRHouse$50,001 - $100,000
Buy2025-05-09Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-09Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-09Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-05Marjorie Taylor GreeneRHouse$1,001 - $15,000
Sell2025-04-29Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
Sell2025-04-09Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-08Rob BresnahanRHouse$1,001 - $15,000
Buy2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-01Julie JohnsonDHouse$1,001 - $15,000
Buy2025-03-31Gilbert Ray Cisneros, Jr.DHouse$15,001 - $50,000
Sell2025-03-24George WhitesidesDHouse$100,001 - $250,000
Sell2025-03-07Josh GottheimerDHouse$1,001 - $15,000
Buy2025-03-05Jefferson ShreveRHouse$15,001 - $50,000
Buy2025-03-04Lloyd DoggettDHouse$1,001 - $15,000
Buy2025-03-03Bruce WestermanRHouse$1,001 - $15,000
Buy2025-01-24Josh GottheimerDHouse$1,001 - $15,000
Sell2025-01-24Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-01-22Ro KhannaDHouse$1,001 - $15,000
Sell2025-01-22Ro KhannaDHouse$1,001 - $15,000
Buy2025-01-21Josh GottheimerDHouse$1,001 - $15,000
Buy2025-01-17Ro KhannaDHouse$1,001 - $15,000
Buy2025-01-16Josh GottheimerDHouse$1,001 - $15,000
Buy2025-01-08Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-01-08Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-01-08Marjorie Taylor GreeneRHouse$1,001 - $15,000
Sell2024-12-31Kevin HernRHouse$100,001 - $250,000
Buy2024-12-24Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2024-12-12Josh GottheimerDHouse$1,001 - $15,000
Buy2024-12-10Lloyd DoggettDHouse$1,001 - $15,000
Buy2024-12-06Virginia FoxxRHouse$1,001 - $15,000
Buy2024-11-26Josh GottheimerDHouse$1,001 - $15,000
Buy2024-11-25Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2024-11-22Josh GottheimerDHouse$1,001 - $15,000
Buy2024-11-15Ro KhannaDHouse$1,001 - $15,000
Buy2024-11-08Jared MoskowitzDHouse$1,001 - $15,000
Sell2024-10-29Tommy TubervilleRSenate$15,001 - $50,000
Sell2024-10-11Ro KhannaDHouse$1,001 - $15,000
Buy2024-09-10Lloyd DoggettDHouse$1,001 - $15,000
Sell2024-09-04John JamesRHouse$1,001 - $15,000
Buy2024-08-07Scott FranklinRHouse$1,001 - $15,000
Buy2024-08-02Ro KhannaDHouse$15,001 - $50,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact